Treatment strategies and risk of central nervous system recurrence in high-grade B-cell and Burkitt lymphoma

Leuk Lymphoma. 2020 Jan;61(1):198-201. doi: 10.1080/10428194.2019.1654097. Epub 2019 Aug 21.

Authors

Dominic P Decker^{1

2}, Pamela C Egan^{1

2

3}, Adam S Zayac^{1

2

3}, Diana O Treaba^{1

4}, Adam J Olszewski^{1

2

3}

Affiliations

¹ The Warren Alpert Medical School of Brown University, Providence, RI, USA.
² Department of Medicine, Rhode Island Hospital, Providence, RI, USA.
³ Division of Hematology-Oncology, Rhode Island Hospital, Providence, RI, USA.
⁴ Department of Pathology, Rhode Island Hospital, Providence, RI, USA.

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
B-Lymphocytes
Burkitt Lymphoma* / diagnosis
Burkitt Lymphoma* / epidemiology
Burkitt Lymphoma* / therapy
Central Nervous System
Humans
Lymphoma, Large B-Cell, Diffuse*
Neoplasm Recurrence, Local

Grants and funding

U54 GM115677/GM/NIGMS NIH HHS/United States